Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MRNA

MRNA - Moderna Inc Stock Price, Fair Value and News

$45.30-0.15 (-0.33%)
Market Closed

41/100

MRNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

41/100

MRNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$42.43

Target 3M

$47.05

Target 6M

$45.45

MRNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRNA Price Action

Last 7 days

-9.0%

Last 30 days

45.4%

Last 90 days

61.0%

Trailing 12 Months

0.8%

MRNA RSI Chart

MRNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRNA Valuation

Market Cap

17.7B

Price/Earnings (Trailing)

-5.68

Price/Sales (Trailing)

2.93

EV/EBITDA

-5.25

Price/Free Cashflow

-6.67

MRNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$42.43

Target 3M

$47.05

Target 6M

$45.45

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

3.2B

Rev. Growth (Yr)

-45.44%

Rev. Growth (Qtr)

615.49%

MRNA Earnings

Earnings (TTM)

-3.1B

Earnings Growth (Yr)

-1.6K%

Earnings Growth (Qtr)

75.76%

MRNA Profitability

EBT Margin

-97.44%

Return on Equity

-33.4%

Return on Assets

-25.68%

Free Cashflow Yield

-14.99%

MRNA Investor Care

Shares Dilution (1Y)

1.52%

Diluted EPS (TTM)

-8.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20245.9B5.0B4.1B3.2B
202315.1B10.7B9.1B6.8B
202222.6B23.0B21.4B19.3B
20212.7B7.0B11.8B18.5B
202052.2M106.1M246.1M803.0M
2019122.1M106.3M81.6M60.2M
2018204.5M192.3M191.6M135.1M
2017132.8M157.1M181.5M205.8M
2016000108.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Moderna Inc

MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEmodernatx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3900

Moderna Inc Frequently Asked Questions

MRNA is the stock ticker symbol of Moderna Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Moderna Inc is 17.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MRNA's fair value in chart for subscribers.

The fair value guage provides a quick view whether MRNA is over valued or under valued. Whether Moderna Inc is cheap or expensive depends on the assumptions which impact Moderna Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNA.

As of Wed Jan 28 2026, MRNA's PE ratio (Price to Earnings) is -5.68 and Price to Sales (PS) ratio is 2.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNA PE ratio will change depending on the future growth rate expectations of investors.